Paying users zone. Data is covered by hidden.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (LLY)


Price to FCFE (P/FCFE)

Difficulty: Intermediate


Free Cash Flow to Equity (FCFE)

Eli Lilly & Co., FCFE calculation

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income (loss) hidden hidden hidden hidden hidden
Net noncash charges hidden hidden hidden hidden hidden
Other changes in operating assets and liabilities, net of acquisitions and divestitures hidden hidden hidden hidden hidden
Net cash provided by operating activities hidden hidden hidden hidden hidden
Purchases of property and equipment hidden hidden hidden hidden hidden
Proceeds from disposals of property and equipment hidden hidden hidden hidden hidden
Net change in short-term borrowings hidden hidden hidden hidden hidden
Proceeds from issuance of long-term debt hidden hidden hidden hidden hidden
Repayments of long-term debt hidden hidden hidden hidden hidden
Free cash flow to equity (FCFE) hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).

Item Description The company
FCFE Free cash flow to equity is the cash flow available to Eli Lilly & Co.’s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Eli Lilly & Co.’s FCFE increased from 2016 to 2017 but then declined significantly from 2017 to 2018.

Price to FCFE Ratio, Current

Eli Lilly & Co., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
No. shares of common stock outstanding hidden
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands) hidden
FCFE per share hidden
Current share price (P) hidden
Valuation Ratio
P/FCFE hidden
Benchmarks
P/FCFE, Competitors1
Abbott Laboratories hidden
AbbVie Inc. hidden
Allergan PLC hidden
Amgen Inc. hidden
Biogen Inc. hidden
Bristol-Myers Squibb Co. hidden
Celgene Corp. hidden
Gilead Sciences Inc. hidden
Johnson & Johnson hidden
Merck & Co. Inc. hidden
Pfizer Inc. hidden
Regeneron Pharmaceuticals Inc. hidden
P/FCFE, Sector
Pharmaceuticals & Biotechnology hidden
P/FCFE, Industry
Health Care hidden

Based on: 10-K (filing date: 2019-02-19).

1 Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.


Price to FCFE Ratio, Historical

Eli Lilly & Co., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands)2 hidden hidden hidden hidden hidden
FCFE per share3 hidden hidden hidden hidden hidden
Share price1, 4 hidden hidden hidden hidden hidden
Valuation Ratio
P/FCFE5 hidden hidden hidden hidden hidden
Benchmarks
P/FCFE, Competitors6
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/FCFE, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/FCFE, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).

1 Data adjusted for splits and stock dividends.

2 See details »

3 2018 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

4 Closing price as at the filing date of Eli Lilly & Co.’s Annual Report.

5 2018 Calculation
P/FCFE = Share price ÷ FCFE per share
= hidden ÷ hidden = hidden

6 Click competitor name to see calculations.

Valuation ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. Eli Lilly & Co.’s P/FCFE ratio declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.